medigraphic.com
ISSN 2307-2113 (Digital)
Revista Cubana de Información en Ciencias de la Salud (ACIMED)

2014, Número 4

<< Anterior Siguiente >>

Revista Cubana de Información en Ciencias de la Salud (ACIMED) 2014; 25 (4)


¿Deberían las revistas médicas dejar de publicar ensayos clínicos financiados por la industria?

Idioma: Español
Referencias bibliográficas: 30
Paginas: 452-458
Archivo PDF: 65.82 Kb.


FRAGMENTO

El debate que se reproduce a continuación fue recogido en la revista British Medical Journal (BMJ) en el mes de enero de 2014 (BMJ. 2014;348:g171 doi: 10.1136/bmj.g171). Su título original fue "Should journals stop publishing research funded by the drug industry?" Aborda un espinoso asunto directamente relacionado con la información que debe o no ser acogida en las revistas médicas.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Godlee F, Malone R, Timmis A, Otto C, Bush A, Pavord I, et al. Journal policy on research funded by the tobacco industry. BMJ. 2013;347:5193.

  2. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2012;12:MR000033.

  3. Gøtzsche PC. Deadly medicines and organised crime: how big pharma has corrupted health care. Radcliffe, 2013.

  4. Krumholz HM, Ross JS, Presler AH, Egilman DS. What have we learnt from Vioxx? BMJ. 2007;334:120-3.

  5. Healy D. Let them eat Prozac. New York University Press, 2004.

  6. Sackett DL, Oxman AD. HARLOT plc: an amalgamation of the world's two oldest professions. BMJ. 2003;327:1442-5.

  7. Goldacre B. Bad pharma. How medicine is broken, and how we can fix it. London: Fourth Estate, 2012.

  8. Serebruany VL, Atar D. Viewpoint: central adjudication of myocardial infarction in outcome-driven clinical trials: common patterns in TRITON, RECORD, and PLATO? Thromb Haemost. 2012;108:412-4.

  9. Scherer RW, Langenberg P, von Elm E. Full publication of results initially presented in abstracts. Cochrane Database Syst Rev. 2007;2:MR000005.

  10. Buchkowsky SS, Jewesson PJ. Industry sponsorship and authorship of clinical trials over 20 years. Ann Pharmacother. 2004;38:579-85.

  11. Wislar JS, Flanagin A, Fontanarosa PB, DeAngelis CD. Honorary and ghost authorship in high impact biomedical journals: a cross sectional survey. BMJ. 2011;343:6128.

  12. Stern S, Lemmens T. Legal remedies for medical ghostwriting: Imposing fraud liability on guest authors of ghostwritten articles. Medical Writing. 2013;22(4):264- 71.

  13. Handel AE, Patel SV, Pakpoor J, Ebers GC, Goldacre B, Ramagopalan SV. High reprint orders in medical journals and pharmaceutical industry funding: casecontrol study. BMJ. 2012;344:421.

  14. Smith R. The trouble with medical journals. Royal Society of Medicine, 2006.

  15. Smith R. Time to open up the finances of medical journals [electronic response to: Handel et al. High reprint orders in medical journals and pharmaceutical industry funding: case-control study]. BMJ. 2012 [citado 12 de agosto de 2014]. Disponible en: www.bmj.com/content/344/bmj.e4212/rr/592345

  16. Dickersin K. Reporting and other biases in studies of Neurontin for migraine, psychiatric/bipolar disorders, nociceptive pain, and neuropathic pain. 2008 [citado 12 de agosto de 2014]. Disponible en: www.pharmalot.com/wpcontent/ uploads/2008/10/neurontin-dickersin-2.pdf

  17. Smith R, Roberts I. Patient safety requires a new way to publish clinical trials. PLoS Clin Trials. 2006;1:6.

  18. Godlee F, Malone R, Timmis A, Otto C, Bush A, Pavord I, et al. Journal policy on research funded by the tobacco industry. BMJ. 2013;347:5193.

  19. Proctor CJ. Journal policy on research funded by the tobacco industry. BMJ. 2013 [citado 12 de agosto de 2014]. Disponible en: www.bmj.com/content/347/bmj.f5193/rr/674388

  20. Smith R. The same arguments mean that journals should stop publishing research funded by the pharmaceutical industry. BMJ. 2013 [citado 12 de agosto de 2014]. Disponible en: www.bmj.com/content/347/bmj.f5193/rr/668130

  21. Bruntland GH. Director-general's address to WHO international conference on tobacco and health. Kobe, Japan, 1999 [citado 12 de agosto de 2014]. Disponible en: www.who.int/director-general/speeches/1999/english/19991115_kobe.html

  22. Van Luijn J, Gribnau F, Leufkens HGM. Superior efficacy of new medicines? Eur J Clin Pharmacol. 2010;66:445-8.

  23. Garattini S, Chalmers I. Patients and the public deserve big changes in evaluation of drugs. BMJ. 2009;338:1025.

  24. McGauran N, Wieseler B, Kreis J, Schüler Y-B, Kölsch H, Kaiser T. Reporting bias in medical research-a narrative review. Trials. 2010;11:37.

  25. Chalmers I, Glasziou P, Godlee F. All trials must be registered and the results published. BMJ. 2013;346:105.

  26. All Trials. All trials registered. All results reported. 2013 [citado 12 de agosto de 2014]. Disponible en: www.alltrials.net/wp-content/uploads/2013/09/What-doesall- trials-registered-and-reported-mean.pdf

  27. Doshi P, Dickersin K, Healy D, Vedula SS, Jefferson T. Restoring invisible and abandoned trials: a call for people to publish the findings. BMJ. 2013;346:2865.

  28. Godlee F, Groves T. The new BMJ policy on sharing data from drug and device trials. BMJ. 2012;345:7888.

  29. Godlee F. Journal policy on research funded by the tobacco industry. BMJ. 2013 [citado 12 de agosto de 2013]. Disponible en: www.bmj.com/content/347/bmj.f5193/rr/671904

  30. Godlee F. Journal policy on research funded by the tobacco industry. BMJ. 2014 [citado 14 de enero de 2014]. Disponible en: http://dx.doi.org/10.1136/bmj.g171




2020     |     www.medigraphic.com